Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Laminin α1 is a genetic modifier of TGF-β1–stimulated pulmonary fibrosis
Chang-Min Lee, … , Chun Geun Lee, Jack A. Elias
Chang-Min Lee, … , Chun Geun Lee, Jack A. Elias
Published September 20, 2018
Citation Information: JCI Insight. 2018;3(18):e99574. https://doi.org/10.1172/jci.insight.99574.
View: Text | PDF
Research Article Pulmonology

Laminin α1 is a genetic modifier of TGF-β1–stimulated pulmonary fibrosis

  • Text
  • PDF
Abstract

The pathogenetic mechanisms underlying the pathologic fibrosis in diseases such as idiopathic pulmonary fibrosis (IPF) are poorly understood. To identify genetic factors affecting susceptibility to IPF, we analyzed a murine genetic model of IPF in which a profibrotic cytokine (TGF-β1) was expressed in the lungs of 10 different inbred mouse strains. Surprisingly, the extent of TGF-β1–induced lung fibrosis was highly strain dependent. Haplotype-based computational genetic analysis and gene expression profiling of lung tissue obtained from fibrosis-susceptible and -resistant strains identified laminin α1 (Lama1) as a genetic modifier for susceptibility to IPF. Subsequent studies demonstrated that Lama1 plays an important role in multiple processes that affect the pulmonary response to lung injury and susceptibility to fibrosis, which include: macrophage activation, fibroblast proliferation, myofibroblast transformation, and the production of extracellular matrix. Also, Lama1 mRNA expression was significantly increased in lung tissue obtained from IPF patients. These studies identify Lama1 as the genetic modifier of TGF-β1 effector responses that significantly affects the development of pulmonary fibrosis.

Authors

Chang-Min Lee, Soo Jung Cho, Won-Kyung Cho, Jin Wook Park, Jae-Hyun Lee, Augustine M. Choi, Ivan O. Rosas, Ming Zheng, Gary Peltz, Chun Geun Lee, Jack A. Elias

×

Figure 2

Strain- and cell-dependent Lama1 expression in lungs from TGF-β Tg mice.

Options: View larger image (or click on image) Download as PowerPoint
Strain- and cell-dependent Lama1 expression in lungs from TGF-β Tg mice....
Lungs from doxycycline-treated TGF-β1 Tg mice on the noted genetic backgrounds were evaluated. (A) Representative Lama1 IHC evaluation comparing C57 and BALB/c TGF-β Tg mice. White arrow indicates Lama1 positive macrophages while blue arrow indicates Lama1 stained area of basement membrane (lightly stained compared to macrophages) (B) Double IHC using anti-Lama1 (green) and anti-CD68 (red) antibodies. Arrows indicate cells stained with, Lama1, CD68 (macrophage specific marker), or both. Scale bars in A and B: 25 μm. (C) Fibroblasts were established from lungs of C57 and BALB/c mice and treated with TGF-β1 for 2 or 24 hours. The levels of Lama1 mRNA were evaluated by qRT-PCR. (D) Western blot evaluation on Smad2 activation in fibroblasts from C57 and BALB/c mice with and without TGF-β stimulation. A, B, and D represent evaluations in a minimum of 3 mice. Values in C represent mean ± SEM of evaluations in a minimum of 5 mice in each group. **P < 0.01, ***P < 0.001 compared with controls with no TGF-β treatment.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts